Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBIT Margin (2019 - 2025)

Avidity Biosciences (RNA) has disclosed EBIT Margin for 7 consecutive years, with 7630.52% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 356090.0% year-over-year to 7630.52%, compared with a TTM value of 3513.63% through Dec 2025, down 3618.0%, and an annual FY2025 reading of 3977.3%, down 49987.0% over the prior year.
  • EBIT Margin was 7630.52% for Q4 2025 at Avidity Biosciences, down from 1513.47% in the prior quarter.
  • Across five years, EBIT Margin topped out at 882.29% in Q1 2021 and bottomed at 8360.9% in Q1 2025.
  • Average EBIT Margin over 5 years is 2976.28%, with a median of 2152.17% recorded in 2022.
  • Peak annual rise in EBIT Margin hit 268747bps in 2025, while the deepest fall reached -618233bps in 2025.
  • Year by year, EBIT Margin stood at 2081.37% in 2021, then rose by 8bps to 1922.17% in 2022, then plummeted by -58bps to 3043.46% in 2023, then plummeted by -34bps to 4069.63% in 2024, then crashed by -87bps to 7630.52% in 2025.
  • Business Quant data shows EBIT Margin for RNA at 7630.52% in Q4 2025, 1513.47% in Q3 2025, and 4448.71% in Q2 2025.